These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 1961278)
41. Medicare and Medicaid statistical supplement, 1996. U.S. Department of Health and Human Services, Health Care Financing Administration. Health Care Financ Rev Stat Suppl; 1996; ():1-472. PubMed ID: 10162839 [No Abstract] [Full Text] [Related]
43. Participants, analysts share preliminary data from the ESRD managed care demonstration project. Neumann ME Nephrol News Issues; 2001 Jul; 15(8):15-6. PubMed ID: 12099225 [No Abstract] [Full Text] [Related]
44. The economic cost of ESRD and Medicare spending for alternative modalities of treatment. United States Renal Data System. Am J Kidney Dis; 1998 Aug; 32(2 Suppl 1):S118-31. PubMed ID: 9713414 [No Abstract] [Full Text] [Related]
45. Study of the Medicare End-Stage Renal Disease program. Rettig RA Am J Kidney Dis; 1990 May; 15(5):491-3. PubMed ID: 2185628 [No Abstract] [Full Text] [Related]
46. Deliberations on and myths about OBRA '87 psychopharmacological medication regulations. Kidder SW J Am Med Dir Assoc; 2003; 4(5):268-73. PubMed ID: 12959656 [No Abstract] [Full Text] [Related]
48. Proposed conditions for coverage directed toward dialysis facilities. Smetanka S Health Care Law Mon; 2005 Apr; ():3-11. PubMed ID: 15895752 [No Abstract] [Full Text] [Related]
49. The use of rehabilitation services by patients with chronic renal failure: results from the National Kidney Dialysis and Kidney Transplantation Study. Evans RW; Manninen DL; Garrison LP; Hart LG AANNT J; 1983 Oct; 10(6):19-25. PubMed ID: 6360186 [No Abstract] [Full Text] [Related]
50. IOM says: X-ray mammography remains the gold standard in breast cancer screening technology. Rollins G Rep Med Guidel Outcomes Res; 2001 Apr; 12(8):1-2, 5. PubMed ID: 12108453 [No Abstract] [Full Text] [Related]
53. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO? Besarab A; McCrea JB ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674 [No Abstract] [Full Text] [Related]
54. Will the bundle improve the way care is delivered? Neumann ME Nephrol News Issues; 2010 Jan; 24(1):8. PubMed ID: 20196495 [No Abstract] [Full Text] [Related]
55. Geographic adjustment in Medicare payment. Institute of Medicine report offers price change recomendations. Ferman JH Healthc Exec; 2011; 26(5):70-1. PubMed ID: 21932623 [No Abstract] [Full Text] [Related]
56. Integrated care models: if patients benefit, so will bottom line. Neumann ME Nephrol News Issues; 2012 Sep; 26(10):8. PubMed ID: 23033620 [No Abstract] [Full Text] [Related]
57. GOP deficit plan gone ... but cuts to Medicare, Medicaid likely to stay. Daly R Mod Healthc; 2011 May; 41(22):8-9. PubMed ID: 21717656 [No Abstract] [Full Text] [Related]
58. The politics of health cost containment: end-stage renal disease. Rettig RA Bull N Y Acad Med; 1980; 56(1):115-38. PubMed ID: 6986928 [No Abstract] [Full Text] [Related]
59. Cyclosporine and the financial plight of organ transplant recipients. Helgeson MD Nephrol News Issues; 1992 Aug; 6(8):12, 16. PubMed ID: 1407062 [No Abstract] [Full Text] [Related]
60. From fee-for-service to capitation: factors driving ESRD reimbursement system change. Day LM Nephrol News Issues; 1997 Apr; 11(4):22-3, 31. PubMed ID: 9287685 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]